Safety of Buprenorphine Transdermal Systems in Subjects With Chronic Nonmalignant Pain - a 28-week Extension Study
NCT01151098
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
189
Enrollment
INDUSTRY
Sponsor class
Conditions
Chronic Nonmalignant Pain
Interventions
DRUG:
Buprenorphine transdermal patch
Sponsor
Purdue Pharma LP